Share Twitter LinkedIn Facebook Email Constantine Tam, MBBS, MD, Consultant Hematologist, Peter MacCallum Cancer Center, Melbourne, Australia, offers his impression of the pivotal clinical data that lead to the recent FDA approval of zanubrutinib.
2025 Leukemia / Lymphoma Updates with Aaron Goodman, MD – UC San Diego – MOASC Hematologic Malignancies 6 Mins Read
Inotuzumab Ozogamicin and Gemtuzumab Ozogamicin: A 2024 Guide to Managing Liver Toxicity and Cancer Treatment for Oncologists [40 Slides] Hematologic Malignancies 5 Mins Read
Non-Malignant Hematology Clinics: Essential Pioneers in the Evolving Hematologic Care Hematologic Malignancies 3 Mins Read